Baldwin Brothers LLC Tg Therapeutics, Inc. Transaction History

Baldwin Brothers LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 18, 2022	SELL	$3.74 - $10.66 $26,180 - $74,620	-7,000 Closed	0 $0
Q1 2022 Apr 13, 2022	BUY	$7.81 - $20.45 $39,050 - $102,250	5,000 Added 250.0%	7,000 $67,000
Q4 2020 Jan 12, 2021	SELL	$25.27 - $54.9 $400,529 - $870,165	-15,850 Reduced 88.8%	2,000 $104,000
Q1 2020 Apr 15, 2020	SELL	$7.14 - $15.99 $71,400 - $159,900	-10,000 Reduced 35.91%	17,850 $176,000
Q4 2019 Jan 29, 2020	SELL	$5.1 - $11.2 $10,200 - $22,400	-2,000 Reduced 6.7%	27,850 $309,000
Q1 2019 Apr 24, 2019	BUY	$4.02 - $8.04 $48,239 - $96,479	12,000 Added 67.23%	29,850 $240,000
Q3 2017 Oct 26, 2017	BUY	$10.0 - $12.7 $178,500 - $226,695	17,850	17,850 $212,000

371

85.9M

3.64M

2.59M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.46B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Baldwin Brothers LLC, based on Form 13F filings with the SEC.

Stay updated on Baldwin Brothers LLC with notifications on news.